Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bcl-2-like protein 1, commonly referred to as Bcl-xL, is a critical anti-apoptotic member of the Bcl-2 family that maintains cellular survival by preserving mitochondrial outer membrane integrity. It functions by binding and sequestering pro-apoptotic proteins, such as BAX and BAK, thereby preventing the release of cytochrome c and the subsequent activation of the caspase cascade. Overexpression of Bcl-xL is a frequent occurrence in various cancers, including lung, breast, and prostate cancers, where it contributes to tumor progression and resistance to conventional therapies. As a result, Bcl-xL has emerged as a significant therapeutic target, leading to the development of BH3 mimetics like navitoclax that disrupt its anti-apoptotic activity. Additionally, Bcl-xL is a primary target in senolytic research, as its inhibition can selectively eliminate senescent cells to potentially treat age-related diseases. A major clinical hurdle in targeting Bcl-xL is its essential role in the survival of mature platelets, meaning that systemic inhibition often results in dose-limiting thrombocytopenia. Current research is focused on overcoming this toxicity through the use of PROTACs, such as DT2216, or antibody-drug conjugates that offer more tissue-specific targeting.
Bcl-xL inhibitors function as BH3 mimetics, binding to the hydrophobic groove of the Bcl-xL protein to displace pro-apoptotic BH3-only proteins or multidomain pro-apoptotic proteins like BAX and BAK, thereby triggering mitochondrial outer membrane permeabilization and apoptosis.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bcl-2-like protein 1 (Bcl-xL) (Bcl-xL).